Search
for
Sort by
Research 571–600 of 774
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Treatment of severe alopecia areata with baricitinib
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
- Successful treatment of alopecia universalis with abrocitinib: a case report
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
- Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
- Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Efficacy of tofacitinib in pediatric alopecia universalis
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2